Engineered red blood cells carrying PCSK9 inhibitors persistently lower LDL and prevent obesity.

Low plasma levels of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) are associated with decreased low-density lipoprotein (LDL) cholesterol and a reduced risk of cardiovascular disease. PCSK9 binds to the epidermal growth factor-like repeat A (EGFA) domain of LDL receptors (LDLR), very low-density...

Full description

Bibliographic Details
Main Authors: Rhogerry Deshycka, Valentino Sudaryo, Nai-Jia Huang, Yushu Xie, Liyan Y Smeding, Moon Kyung Choi, Hidde L Ploegh, Harvey F Lodish, Novalia Pishesha
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0259353